PreSize Net medical device software for realistic surgery planning: next-generation scalable technology for selecting the best surgical scenario for every patient

我们的目标是让心血管手术更高效、更安全。该项目增加了我们PreSize医疗设备软件的功能，这是一种新颖的临床决策支持解决方案，可以帮助外科医生通过逼真的手术模拟来计划和排练血管内的植入。使用尖端的计算模型，我们最大限度地利用可用的患者扫描和设备力学来准确预测每个患者血管解剖中的设备行为。这使得临床医生可以为每个患者选择最好的设备，从而减少医院和我们社会的并发症数量和相关的手术成本。这个项目的特别创新之处在于，PreSize平台将被开发成尽可能容易访问，旨在最大限度地扩大其在整个医疗系统的覆盖范围和好处。我们是一家屡获殊荣的初创公司，专门为将这项技术引入医院而创建。我们拥有一支由工程、软件、商业、法律和监管专家组成的强大团队，以前一直得到Innovate UK赠款的支持(目前正在运营BMC早期奖，直到2022年4月)，并得到皇家工程院的持续支持。我们之前项目的成果获得了许多奖项，包括：*NHS 2017年来自Health Enterprise East(HEE)的创新奖*被连线杂志评为2018年最佳医疗初创企业*BioMedEng创新奖2021，以表彰我们的创始人的开创性工作，这些工作导致了支持医疗干预的新技术。我们还被选为数字健康伦敦加速器计划的一部分，以前是飞利浦医疗加速器全球选定的6家初创企业之一，并在一般媒体上进行了专题报道，例如，在《福布斯》(《致力于改变世界的创始人》)和《连线》(《从人工智能医生到3D-X光，医疗保健的未来已经在这里》)，以及《泰晤士报》、《金融时报》、《每日电讯报》等，我们的目标是将牛津心跳发展成为临床决策支持工具的领先提供商，促进英国经济及其在医疗保健领域的国际领先地位，改善所有人的医疗保健，并定义明天的医学。

Our goal is to make cardiovascular surgeries more efficient and safe. This project increases the power of our PreSize medical device software - a novel clinical decision-support solution that helps surgeons plan and rehearse implant placements inside blood vessels with realistic surgery simulations. Using cutting-edge computational modelling, we make the best use of available patient scans and device mechanics to accurately predict the behaviour of devices inside each patient's vessel anatomy. This allows clinicians to select the best device for every patient, reducing the number of complications and associated cost of surgeries for hospitals and our society. What is especially innovative with this project is that the PreSize platform will be developed to be as easily accessible as possible, aimed to maximise its reach and benefits across the healthcare system.We are an award-winning start-up company specifically created to bring this technology to hospitals. With a strong team of engineering, software, commercial, legal and regulatory experts, we have been previously supported by Innovate UK grants (currently running BMC Early Stage award until April 2022) and receive ongoing support by The Royal Academy of Engineering. The results of our previous projects have received numerous awards, including:* NHS Innovation Award 2017 from Health Enterprise East (HEE)* "Best Healthcare Start-up of 2018" by WIRED magazine* BioMedEng Innovation Prize 2021 for recognition of our founder's 'ground-breaking work which has led to new technologies that support medical interventions'We were also selected to be part of the Digital Health London Accelerator programme, and were previously one of the 6 startups selected globally by Philips Healthcare Accelerator, as well as featured in the general press, e.g., in Forbes ("Founders striving to change the world") and WIRED ("From AI doctors to 3D X-rays, the future of healthcare is already here"), as well as The Times, Financial Times, The Telegraph, etc.Our aim is to grow Oxford Heartbeat to become the leading provider of clinical decision support tools, to boost the UK economy and its international leadership in healthcare, to improve healthcare for all, and define the medicine of tomorrow.